Obermatt

Innospec

NSQ:IOSP · US45768S1050
ChemicalsMedium

360

84
EV / EBIT70
Price / Owner Earnings42
Owner Earnings Yield84
Dividend Yield71
Price/Sales54
EV / Gross Profit72
Price/Book57
Return on Capital56
Cash Return on Capital65
Return on Equity48
EBIT Margin29
Gross Profitability79
Cash Conversion18
Accruals23
Owner Earnings Margin53
Sales growth36
Profit Growth37
Long-Term EPS Growth44
Owner Earnings Growth89
Reinvestment32
Price momentum25
Debt load100
Refinancing73
Debt Payback100
Liquidity98
Analyst ratings83
Opinion Changes50
Price Target Upside58
Market mood77
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Innospec clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryChemicals
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded1998
Employees1,079
ISINUS45768S1050
Last UpdateApr 2, 2026
Themes
CleanTechPollution ControlChemicalInformation TechnologyManufacturing

Description

Innospec Inc. develops, manufactures, blends, markets and supplies a wide range of specialty chemicals to customers in the Americas, Europe, the Middle East, Africa and the Asia-Pacific. The company’s Performance Chemicals business creates innovativ…

Analysis

Middle-of-the-road

Innospec Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 19.9×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 6% a year, against analyst forecasts of 8%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
100
2023202420252026

All-time high

100

Mar 2026

All-time low

56

Jan 2023

Average rank

78

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
54
49
43
50
Price/Earnings
45
41
39
32
Price/Book
57
40
30
59
Dividend Yield
71
57
32
35
Value (overall)
63
42
28
33

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Innospec with its peers
NewMarket
NYQ:NEU
68
CountryUSA
IndustryChemicals
SizeLarge
Full Stock Analysis →
Global Partners
NYQ:GLP
59
CountryUSA
IndustryOil, Gas & Consumable Fuels
SizeLarge
Full Stock Analysis →
Ascent Industries
NMQ:ACNT
35
CountryUSA
IndustryChemicals
SizeSmall
Full Stock Analysis →
Alto Ingredients
NAQ:ALTO
82
CountryUSA
IndustryChemicals
SizeSmall
Full Stock Analysis →
Ingevity
NYQ:NGVT
18
CountryUSA
IndustryChemicals
SizeMedium
Full Stock Analysis →
Hawkins
NSQ:HWKN
66
CountryUSA
IndustryChemicals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →